The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting amyloid-β in glaucoma treatment
Open accessAbstract
The development of the devastating neurodegenerative condition, Alzheimer's disease, is strongly associated with amyloid-β (Aβ) deposition, neuronal apoptosis, and cell loss. Here, we provide evidence that implicates these same mechanisms in the retinal disease glaucoma, a major cause of irreversible blindness worldwide, previously associated simply with the effects of intraocular pressure. We show that Aβ colocalizes with apoptotic retinal ganglion cells (RGC) in experimental glaucoma and induces significant RGC apoptosis in vivo in a dose- and time-dependent manner. We demonstrate that targeting different components of the Aβ formation and aggregation pathway can effectively reduce glaucomatous RGC apoptosis in vivo , and finally, that combining treatments (triple therapy) is more effective than monotherapy. Our work suggests that targeting the Aβ pathway provides a therapeutic avenue in glaucoma management. Furthermore, our work demonstrates that the combination of agents affecting multiple stages in the Aβ pathway may be the most effective strategy in Aβ-related diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The number of people with glaucoma worldwide in 2010 and 2020
Quigley, H. A. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2005.081224 · Cited by 7,394
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
(1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00223-2 · Cited by 1,599
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324
Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis.
Quigley, H. A., Nickells, R. W., Kerrigan, L. A., Pease, M. E., Thibault, D., & Zack, D. J. (1995) · PubMed · Cited by 935
Pepys, M. B. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 559
A Rat Model of Chronic Pressure-induced Optic Nerve Damage
MORRISON, J. C., MOORE, C. G., DEPPMEIER, L. M. H., GOLD, B. G., MESHUL, C. K., & JOHNSON, E. C. (1997) · Experimental Eye Research · doi:10.1006/exer.1996.0184 · Cited by 519
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192203399 · Cited by 447
Iseri, P. K., Altinaş, Ö., Tokay, T., & Yüksel, N. (2006) · Journal of Neuro-Ophthalmology · doi:10.1097/01.wno.0000204645.56873.26 · Cited by 400
Guo, L., Moss, S. E., Alexander, R. A., Ali, R. R., Fitzke, F. W., & Cordeiro, M. F. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0832 · Cited by 350
Self-citationMorphological and functional retinal impairment in Alzheimer's disease patients
Parisi, V., Restuccia, R., Fattapposta, F., Mina, C., Bucci, M. G., & Pierelli, F. (2001) · Clinical Neurophysiology · doi:10.1016/s1388-2457(01)00620-4 · Cited by 344
Intraocular Pressure and Glaucoma
Sommer, A. (1989) · American Journal of Ophthalmology · doi:10.1016/0002-9394(89)90221-3 · Cited by 340
Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension.
McKinnon, S. J., Lehman, D. M., Kerrigan, L. A., Merges, C. A., Pease, M. E., Kerrigan, D., Ransom, N. L., Tahzib, N. G., Reitsamer, H. A., Levkovitch-Verbin, H., et al. (2002) · PubMed · Cited by 334
Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina
Blanks, J. C., Torigoe, Y., Hinton, D. R., & Blanks, R. H. I. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00010-3 · Cited by 330
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL
Blanks, J. C., Schmidt, S. Y., Torigoe, Y., Porrello, K. V., Hinton, D. R., & Blanks, R. H. I. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00009-7 · Cited by 287
Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration
Cordeiro, M. F., Guo, L., Luong, V., Harding, G., Wang, W., Jones, H. E., Moss, S. E., Sillito, A. M., & Fitzke, F. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405479101 · Cited by 267
Self-citationLee, P. P. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.1.12 · Cited by 255
Bayer, A. U., Keller, O. N., Ferrari, F., & Maag, K.-P. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01196-5 · Cited by 229
In vivo neurotoxicity of beta-amyloid [β(1–40)] and the β(25–35) fragment
Kowall, N. W., McKee, A. C., Yankner, B. A., & Beal, M. F. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90053-z · Cited by 224
Naskar, R., Wissing, M., & Thanos, S. (2002) · PubMed · Cited by 209
Lipton, S. A. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6s610 · Cited by 194
Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent.
Cordeiro, M. F., GAY, J. A., & Khaw, P. T. (1999) · PubMed · Cited by 192
Self-citationLevkovitch-Verbin, H., Quigley, H. A., Martin, K. R. G., Zack, D. J., Pease, M. E., & Valenta, D. F. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0646 · Cited by 189
Oliver, J. E., Hattenhauer, M. G., Herman, D., Hodge, D. O., Kennedy, R., Fang-Yen, M., & Johnson, D. H. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01403-4 · Cited by 181
Alzheimer amyloid aβ1-42 channels: Effects of solvent, pH, and congo red
Hirakura, Y., Lin, M., & Kagan, B. L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990815)57:4<458::aid-jnr5>3.0.co;2-4 · Cited by 180
Vitreous fluid levels of β-amyloid(1–42) and tau in patients with retinal diseases
Yoneda, S., Hara, H., Hirata, A., Fukushima, M., Inomata, Y., & Tanihara, H. (2005) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-004-0156-x · Cited by 170
Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina.
Löffler, K. U., Edward, D. P., & Tso, M. O. M. (1995) · PubMed · Cited by 169
Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red.
Hirakura, Y., Lin, M., & Kagan, B. L. (1999) · PubMed · Cited by 151
Cordeiro, M. F., Reichel, M. B., Gay, J. A., D'Esposita, F., Alexander, R., & Khaw, P. T. (1999) · PubMed · Cited by 103
Self-citationCurrent and Emerging Pharmacological Treatment Options for Dementia
Ringman, J. M., & Cummings, J. L. (2006) · Behavioural Neurology · doi:10.1155/2006/315386 · Cited by 86
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Farlow, M. R. (2004) · PubMed · Cited by 86
β‐secretase as a target for the treatment of Alzheimer's disease
Citron, M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10393 · Cited by 81
Orthostatic hypotension. A primary care primer for assessment and treatment.
Sclater, A. L., & Alagiakrishnan, K. (2004) · PubMed · Cited by 63
Novel approaches for immunotherapeutic intervention in Alzheimer's disease
Vasilevko, V., & Cribbs, D. H. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.019 · Cited by 39
Wostyn, P. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.01.013 · Cited by 31
Guo, L. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.058941 · Cited by 31
Self-citation
Cited by
The retina as a window to the brain—from eye research to CNS disorders
London, A., Benhar, I., & Schwartz, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.227 · Cited by 1,403
Quigley, H. A. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61423-7 · Cited by 1,121
Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672
At the interface of sensory and motor dysfunctions and Alzheimer’s disease.
Albers, M. W., Gilmore, G. C., Kaye, J., Murphy, C., Wingfield, A., Bennett, D. A., Boxer, A. L., Buchman, A. S., Cruickshanks, K. J., Devanand, D. P., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.514 · Cited by 589
microRNA dysregulation in neurodegenerative diseases: A systematic review
Juźwik, C. A., S. Drake, S., Zhang, Y., Paradis-Isler, N., Sylvester, A., Amar-Zifkin, A., Douglas, C., Morquette, B., Moore, C. S., & Fournier, A. E. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101664 · Cited by 426
Metadata
- Authors
- Guo, L., Salt, T. E., Luong, V., Wood, N., Cheung, W., Maass, A., Ferrari, G., Russo-Marie, F., Sillito, A. M., Cheetham, M. E., Moss, S. E., Fitzke, F. W., & Cordeiro, M. F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-08-14
- Volume
- 104
- Issue
- 33
- Pages
- 13444-13449
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2044468617
- Cited by
- 342
- References
- 39
- FWCI
- 18.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.